Sarcoidosis 相关的肺高血压
Laurent Savale1, Peter Dorfmüller2, Athénaïs Boucly1
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of Respiratory and Intensive CareMedicine, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
肺高血压是晚期沙尔科毒症的严重并发症,导致呼吸短促和生存率降低. 需要更多的研究来指导与沙尔科毒症相关的肺高血压的治疗.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
背景情况:
- 肺高血压 (PH) 是晚期沙尔科毒症的一个严重并发症.
- 由于各种潜在机制,它可以表现为毛囊前或毛囊后PH.
- Sarcoidosis 与相关的PH显著损害了运动能力,导致呼吸障碍,并降低了生存率.
研究的目的:
- 审查肺高血压在肉类发病中的机制和影响.
- 为了突出缺乏与 Sarcoidosis 相关的PH的具体管理指南.
- 强调对向治疗的进一步研究的需要.
主要方法:
- 文献综述和现有证据的综合研究,关于与沙尔科毒症相关的肺高血压.
- 对导致肺压升高的病理生理机制的分析.
- 对沙尔科病患者PH的临床影响和预后意义的评估.
主要成果:
- Sarcoidosis 可以导致毛囊前和毛囊后肺高血压.
- 相关PH有助于显著的运动性呼吸障碍和减弱的运动耐受性.
- 在患有沙尔科毒症相关PH的患者中,生存显著受到损害.
结论:
- 肺高血压是晚期沙尔科病的危险并发症,危及生命.
- 目前的证据不足以制定具体的管理准则.
- 进一步的研究至关重要,以确定受益于肺动脉高血压向和/或免疫抑制疗法的患者子组.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...


